Vivos Therapeutics (VVOS) Cash & Equivalents (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Cash & Equivalents data on file, last reported at $2.1 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 8.26% year-over-year to $2.1 million in Q1 2026; TTM through Mar 2026 was $2.1 million, a 8.26% decrease from a year earlier, with the FY2025 full-year figure at $2.0 million, down 67.59% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $2.1 million, up from $2.0 million in the prior quarter.
• Over the last five years, Cash & Equivalents for VVOS reached as high as $17.8 million in Q1 2022 and fell as low as $988000.0 in Q3 2023.
• Historically, Cash & Equivalents has averaged $5.3 million across 5 years, with a median of $3.9 million in 2023.
• Across the five-year window, Cash & Equivalents tumbled 85.34% in 2022 and surged 537.65% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $3.5 million in 2022, then slumped by 53.31% to $1.6 million in 2023, then surged by 281.01% to $6.3 million in 2024, then tumbled by 67.59% to $2.0 million in 2025, then rose by 3.99% to $2.1 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $2.1 million in Q1 2026, $2.0 million in Q4 2025, and $3.1 million in Q3 2025.